{"cluster": 42, "subcluster": 11, "abstract_summ": "We also postulate that until a specific vaccine is developed, SARS-CoV-2 vulnerable populations could be immunized with BCG vaccines to attain heterologous nonspecific protection from the new coronavirus.In under 6 months, since SARS-CoV-2 was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development with 9 already recruiting into clinical trials posted on clinicaltrials.gov.Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 \u2013 the virus that causes COVID-19 - currently undergoing early phase human trials.This may pave the way for arriving at efficient prevention strategies as well as vaccine development.CONCLUSION: A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes.", "title_summ": "To The Progression Of SARS-CoV-2 Pandemic?Vaccines for COVID-19: the current state of playTowards effective COVID-19 vaccines: Updates, perspectives and challenges (Review)Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some CountriesSARS-CoV-2 Vaccines: Status ReportDefining Protective Epitopes for COVID\u201019 Vaccination ModelsCalling for an exponential escalation scheme in vaccine development for COVID-19On setting expectations for a SARS-CoV-2 VaccineThe role of passive immunization in the age of SARS-CoV-2: an update[Progress and analysis on the development of 2019-nCoV vaccine].Is Global BCG Vaccination Coverage Relevant", "title_abstract_phrases": "This may pave the way for arriving at efficient prevention strategies as well as vaccine development.Calling for an exponential escalation scheme in vaccine development for COVID-19PURPOSE: COVID-19 as a pandemic calls for rapid development of vaccines.We also postulate that until a specific vaccine is developed, SARS-CoV-2 vulnerable populations could be immunized with BCG vaccines to attain heterologous nonspecific protection from the new coronavirus.In under 6 months, since SARS-CoV-2 was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development with 9 already recruiting into clinical trials posted on clinicaltrials.gov.Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 \u2013 the virus that causes COVID-19 - currently undergoing early phase human trials."}